BIIB Relative Valuation
BIIB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BIIB is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for BIIB's competitors is 10.77, providing a benchmark for relative valuation. Biogen Inc Corp (BIIB) exhibits a P/S ratio of 1.99, which is -81.48% above the industry average. Given its robust revenue growth of 6.13%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Biogen Inc (BIIB) currently overvalued or undervalued?
What is Biogen Inc (BIIB) fair value?
How does BIIB's valuation metrics compare to the industry average?
What is the current P/B ratio for Biogen Inc (BIIB) as of May 19 2025?
What is the current FCF Yield for Biogen Inc (BIIB) as of May 19 2025?
What is the current Forward P/E ratio for Biogen Inc (BIIB) as of May 19 2025?